Project Grant R01CA303099
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $640K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- This $458,698 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of Michigan to identify cellular and molecular mechanisms underlying therapy resistance and disease relapse in acute myeloid leukemia (AML). The project aims to characterize genes and pathways that confer growth advantages to leukemic stem cells, enabling them to persist and regenerate disease after initial clinical remission. This 5-year...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Case Western Reserve University to conduct research aimed at understanding the fundamental biological mechanisms of acute myeloid leukemia (AML) and developing new therapeutic approaches. The $491,357 award supports investigations into using proteasome inhibitors and an mTORC1 activator molecule to induce metabolic stress and resensitize AML cells to treatment, particularly...
- This $495,715 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The project aims to develop faithful preclinical models, including genetically engineered mouse models and patient-derived xenografts, to study the genetic events and disease progression from...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research at the University of Texas MD Anderson Cancer Center to investigate the role of targeting the ATPases BRG1/BRM in the treatment of acute myeloid leukemia (AML). The $542,663 award, provided from April 2025 through March 2030, will fund preclinical studies on the efficacy of two novel targeted agents, FHD-286 and AU15330, to treat AML with MLL rearrangement or mutant NPM1,...
- This $683,472 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel targeted therapy for acute myeloid leukemia (AML). The principal investigators at the University of Cincinnati are conducting preclinical research to evaluate a differentiation-inducing agent (HOSU-53) that targets the mitochondrial enzyme DHODH. The goal is to promote AML cell differentiation, activate the immune system, and induce ferroptosis to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $734,435.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at overcoming resistance to BH3 mimetic drugs in the treatment of acute myeloid leukemia (AML), particularly in older patients. The key objectives are to define the molecular mechanisms underlying BH3 mimetic resistance in AML and evaluate whether targeting the ADSS2 enzyme,...
- This Project Grant award of $502,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Case Western Reserve University focused on developing a small-molecule degrader called SISU-102 to target leukemic stem cells (LSCs) in acute myeloid leukemia (AML). The key objectives are to further investigate the impacts of these HSF1 degraders on LSC self-renewal, identify sensitive and resistant AML subtypes, and explore the underlying mechanisms. This...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $487,542 to the Beckman Research Institute of the City of Hope to conduct research aimed at understanding the role of mitochondrial RNA methylation in acute myeloid leukemia (AML), particularly for high-risk AML subtypes. The key objectives are to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, dissect...
- This federal Project Grant award of $344,111.00 was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to Loyola University of Chicago's Health Sciences Campus division. The grant supports research aimed at understanding the fundamental biological mechanisms of myelodysplastic syndromes (MDS), a group of bone marrow failure diseases that can transform into acute myeloid leukemia. The research focuses on targeting "panoptotic pathways" -...